NEHI Recommends Implementing Value-Based Contracts With High-Cost Oncology Treatments
This article was originally posted by AJMC on November 12, 2017. Perhaps the greatest obstacle impeding patient access to the newest, most cutting-edge cancer drugs is the high cost associated with them. Although several of the newer oncology drugs are backed by strong clinical evidence and have demonstrated promising real-world outcomes, payers remain reluctant to finance these costly drugs for consumers.
In response to this growing issue, the Network for Excellence in Hea